- Home
- VALN
VALN
Valneva SE
as 04-18-2025 1:44pm EST
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.
| Founded: | 2012 | Country: | France |
| Employees: | N/A | City: | N/A |
| Market Cap: | 510.7M | IPO Year: | 2021 |
| Target Price: | $16.00 | AVG Volume (30 days): | 142.9K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.09 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.62 - $9.50 | Next Earning Date: | 05-06-2025 |
| Revenue: | $175,564,758 | Revenue Growth: | 10.32% |
| Revenue Growth (this year): | 19.17% | Revenue Growth (next year): | 26.31% |
Latest Valneva SE News
VALN Breaking Stock News: Dive into VALN Ticker-Specific Updates for Smart Investing
GlobeNewswire
a day ago
Valneva Provides Update on ACIP Recommendation for its Chikungunya Vaccine IXCHIQ® Among U.S. Travelers
GlobeNewswire
3 days ago
Valneva to Participate in Multiple Events at the 25th World Vaccine Congress, including a Presentation on its Chikungunya Vaccine IXCHIQ®
Pharmaceutical Technology
4 days ago
Valneva’s single-dose chikungunya vaccine authorised in Brazil
MT Newswires
5 days ago
Valneva Gets Marketing Authorization for IXCHIQ Vaccine in Brazil
GlobeNewswire
5 days ago
Valneva Receives First Marketing Authorization for IXCHIQ® in a Chikungunya Endemic Country
Zacks
9 days ago
VALN Doses First Infant With Shigella Vaccine in Mid-Stage Study
GlobeNewswire
10 days ago
Valneva and LimmaTech Announce First Vaccination in Phase 2 Infant Study of Tetravalent Shigella Vaccine Candidate S4V2
Simply Wall St.
11 days ago
Exploring Three High Growth Tech Stocks In Europe
Compare VALN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "VALN Valneva SE - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.